生产企业：Madrigal Pharmaceuticals
MGL-3196 has been used in trials studying the treatment of Non-alcoholic steatohepatitis and Heterozygous Familial Hypercholesterolemia.
MGL-3196 has been used in trials studying the treatment of Non-alcoholic steatohepatitis and Heterozygous Familial Hypercholesterolemia.
Thyroid hormone receptor beta (THR-β) agonist
Rezdiffra (resmetirom) is the first FDA-approved treatment for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis, approved in 2024.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
